Waters Corporation reported a 4% increase in sales to $740 million for Q3 2024, surpassing expectations. GAAP EPS reached $2.71, while non-GAAP EPS was $2.93, both exceeding guidance. The company raised its full-year sales and EPS guidance, anticipating 5% to 7% constant currency growth in Q4.
Sales exceeded guidance, growing 4% as reported and in constant currency.
Instruments returned to growth, with recurring revenue growing high single-digits in constant currency.
All reported regions returned to growth, with sales increasing across all end markets, led by Pharma & Industrial.
GAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, driven by strong operational performance and favorable market conditions.
Waters Corporation anticipates fourth quarter 2024 constant currency sales growth to be in the range of +5.0% to +7.0% and non-GAAP EPS to be in the range of $3.90 to $4.10.
Visualization of income flow from segment revenue to net income